Search Results

Vandetanib: Photosensitivity: case report

Source: Reactions, Volume 1, Number 1282, 2009-12-12 , pp. 37-37(1)

Publisher: Adis International

Molecular Targets in Malignant Pleural Mesothelioma Treatment

Authors: Pasello, Giulia; Favaretto, Adolfo

Source: Current Drug Targets, Volume 10, Number 12, December 2009 , pp. 1235-1244(10)

Publisher: Bentham Science Publishers

Vandetanib: First report of corneal verticillata: case report

Source: Reactions, Volume 1, Number 1268, 2009-09-05 , pp. 29-30(2)

Publisher: Adis International

Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer

Authors: Rossi, A.; Maione, P.; Ferrara, M. L.; Sacco, P. C.; Schettino, C.; Bareschino, M. A.; Gridelli, C.

Source: Current Medicinal Chemistry, Volume 16, Number 30, October 2009 , pp. 3919-3930(12)

Publisher: Bentham Science Publishers

According to a new report by Decision Resources, the launch of targeted agents and the increased use of existing agents

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 582, 2009-07-11 , pp. 11-11(1)

Publisher: Adis International

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner

Authors: Flaig, Thomas W.; Su, Lih-Jen; McCoach, Caroline; Li, Yuan; Raben, David; Varella-Garcia, Marileila; Bemis, Lynne T.

Source: BJU International, Volume 103, Number 12, June 2009 , pp. 1729-1737(9)

Publisher: Blackwell Publishing

Mode of action and clinical impact of VEGF signaling inhibitors

Authors: Soltau, Jens; Drevs, Joachim

Source: Expert Review of Anticancer Therapy, Volume 9, Number 5, May 2009 , pp. 649-662(14)

Publisher: Expert Reviews

An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer

Authors: de Boer, R.; Humblet, Y.; Wolf, J.; Nogov, L.; Ruffert, K.; Milenkova, T.; Smith, R.; Godwood, A.; Vansteenkiste, J.

Source: Annals of Oncology, Volume 20, Number 3, 12 March 2009 , pp. 486-491(6)

Publisher: Oxford University Press

Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer

Authors: Mukherji, Deborah; Spicer, James

Source: Expert Opinion on Investigational Drugs, Volume 18, Number 3, March 2009 , pp. 293-301(9)

Publisher: Informa Healthcare

Targeting Aromatase and Estrogen Signaling in Human Non-Small Cell Lung Cancer

Authors: Márquez-Garbán, Diana C.; Chen, Hsiao-Wang; Goodglick, Lee; Fishbein, Michael C.; Pietras, Richard J.

Source: Annals of the New York Academy of Sciences, Volume 1155, Number 1, February 2009 , pp. 194-205(12)

Publisher: Blackwell Publishing

New avenues for second-line treatment of metastatic non-small-cell lung cancer

Authors: Gridelli, Cesare; Maione, Paolo; Rossi, Antonio; Falanga, Marzia; Bareschino, Marianna; Schettino, Clorinda; Colantuoni, Giuseppe; Guerriero, Ciro; Nicolella, Dario; Rossi, Emanuela; Ferrara, Marianna Luciana; Palazzolo, Giovanni

Source: Expert Review of Anticancer Therapy, Volume 9, Number 1, January 2009 , pp. 115-124(10)

Publisher: Expert Reviews

Vandetanib brings a glimmer of hope to lung cancer patients?

Source: Inpharma, Volume 1, Number 1666, 2008-11-29 , pp. 13-13(1)

Publisher: Adis International

The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

Authors: PALAYEKAR; HERZOG

Source: International Journal of Gynecological Cancer, Volume 18, Number 5, September/October 2008 , pp. 879-890(12)

Publisher: Blackwell Publishing

Promising Newer Molecular-Targeted Therapies in Head and Neck Cancer

Authors: Wang, Lili X.; Agulnik, Mark

Source: Drugs, Volume 68, Number 12, 2008 , pp. 1609-1619(11)

Publisher: Adis International

Combined anti-proliferative and anti-angiogenic strategies for cancer

Authors: Bar, Jair; Onn, Amir

Source: Expert Opinion on Pharmacotherapy, Volume 9, Number 5, April 2008 , pp. 701-715(15)

Publisher: Informa Healthcare

Vandetanib in combination with docetaxel does not appear to be a viable second-line therapy option for patients with advanced breast cancer

Source: Inpharma, Volume 1, Number 1620, 2008-01-12 , pp. 14-14(1)

Publisher: Adis International

Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity

Authors: Troiani, Teresa; Cascone, Tina; Heymach, John; Ciardiello, Fortunato

Source: Current Cancer Therapy Reviews, Volume 3, Number 4, November 2007 , pp. 236-241(6)

Publisher: Bentham Science Publishers

Epidermal growth factor receptor inhibitors in non-small-cell lung cancer

Authors: Cascone, Tina; Martinelli, Erika; Morelli, Maria Pia; Morgillo, Floriana; Troiani, Teresa; Ciardiello, Fortunato

Source: Expert Opinion on Drug Discovery, Volume 2, Number 3, March 2007 , pp. 335-348(14)

Publisher: Informa Healthcare

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

Authors: Herbst, Roy S; Heymach, John V; O'Reilly, Michael S; Onn, Amir; Ryan, Anderson J

Source: Expert Opinion on Investigational Drugs, Volume 16, Number 2, February 2007 , pp. 239-249(11)

Publisher: Informa Healthcare

Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors—a novel antiproliferative/antiangiogenic strategy in thyroid cancer

Authors: Hoffmann, S.; Gläser, S.; Wunderlich, A.; Lingelbach, S.; Dietrich, C.; Burchert, A.; Müller, H.; Rothmund, M.; Zielke, A.

Source: Langenbeck's Archives of Surgery, Volume 391, Number 6, November 2006 , pp. 589-596(8)

Publisher: Springer